Compare MDU & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDU | LQDA |
|---|---|---|
| Founded | 1924 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | MDU | LQDA |
|---|---|---|
| Price | $20.68 | $37.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $22.00 | ★ $38.60 |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 02-05-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,876,593,000.00 | $69,216,000.00 |
| Revenue This Year | $9.90 | $1,005.03 |
| Revenue Next Year | $3.93 | $204.13 |
| P/E Ratio | $22.97 | ★ N/A |
| Revenue Growth | N/A | ★ 343.41 |
| 52 Week Low | $15.04 | $11.26 |
| 52 Week High | $21.49 | $41.57 |
| Indicator | MDU | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | 60.22 |
| Support Level | $20.11 | $29.41 |
| Resistance Level | $20.44 | $41.57 |
| Average True Range (ATR) | 0.32 | 3.03 |
| MACD | 0.11 | 0.43 |
| Stochastic Oscillator | 99.62 | 68.38 |
MDU Resources Group Inc operates in three business segments, which include the electric segment, which generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming; The natural gas distribution segment distributes natural gas in those states, as well as in Idaho, Minnesota, Oregon, and Washington; The pipeline segment provides natural gas transportation and underground storage services through a regulated pipeline system in the Rocky Mountain and northern Great Plains regions of the United States.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.